Technology Innovations and Growth Opportunities in Inhaled Therapeutics
Nanoparticle-based Formulation to Drive Transformational Growth Across Inhaled Vaccines and Monoclonal Antibodies
Inhalation drug delivery involves administering drugs to the lungs through the mouth (pulmonary route) or nose (intranasal route), enabling them to bypass the blood-brain barrier. Small molecules have been the main focus for inhalation delivery, but recent R&D and increased interest in inhalable COVID-19 vaccines have led to a shift toward inhalable biologics for conditions where injection delivery is the norm.
This Frost & Sullivan study highlights important formulations for inhalable biologics and examines the factors that drive or limit market growth. The research examines the pipeline of monoclonal antibodies and vaccines in development and evaluates R&D trends, partnership and collaboration trends, funding and investment analysis, patent analysis, and the outlook for inhalable biologics. The study identifies significant growth opportunities for industry players in the field.
Questions this study answers:
1. What factors drive or limit the industry’s growth?
2. What are the innovative methods for formulating inhalable biologics?
3. What does the pipeline analysis for inhalable vaccines and monoclonal antibodies look like?
4. What are the R&D trends and projected developments of the technologies?
5. What are the funding evaluations, patent evaluations, regulatory environments, and trends for partnerships and collaborations for inhalable biologics?
6. What are the growth opportunities for technology developers in the inhalable biologics space?
- Strategic Imperatives
- Why Is It Increasingly Difficult to Grow? The Strategic Imperative 8™: Factors Creating Pressure on Growth
- The Strategic Imperative 8™
- The Impact of the Top 3 Strategic Imperatives on the Inhaled Therapeutics Industry
- Growth Opportunities Fuel the Growth Pipeline Engine™
- Research Methodology
- Growth Opportunity Analysis
- Scope of Analysis
- The Need for Inhalation Biologics Formulation
- Inhalation Drug Delivery—Introduction
- Segmentation—Formulations for Drug Inhalation
- Pros and Cons of Formulation and Drug Delivery Systems for Inhalation
- Examples of Novel Formulations and Drug Delivery System for Inhalable Biologics
- Promising Inhalation Therapy—Advantages of Inhalational Monoclonal Antibodies (mAbs) and Vaccines
- Growth Drivers
- Growth Restraints
- Industry Assessment and Analysis
- Pipeline Analysis of Inhaled Vaccines and mAbs
- Vaccines and mAbs under Clinical Development
- Primary Technologies—AttenuBlock Platform Technology (Codon Deoptimization for Live Attenuated Vaccine Candidates)
- Primary Technologies—Nanoemulsion Platform (Intranasal Adjuvant Technology)
- Innovation Ecosystem
- R&D Trends
- Collaboration and Partnership Trends
- Funding and Investment Analysis
- Patent Analysis
- Future Roadmap
- Growth Opportunity Universe
- Growth Opportunity 1: Drug Repurposing Using Nanotechnology to Produce a Nebulizer Solution
- Growth Opportunity 2: Partnering with a CDMO that Offers End-toend Services
- Growth Opportunity 3: Gene-based Antibody Delivery for Safe Inhaled Administration
- Next Steps
- Your Next Steps
- Why Frost, Why Now?
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook